First magnesium sulfate product WHO prequalified
A health worker checks blood pressure of a pregnant woman at Neshuro District Hospital in Mwenezi, Zimbabwe, in 2011. ©UNICEF/Pirozzi
Inresa Arzneimittel GmbH have achieved WHO prequalification for their magnesium sulfate heptahydrate 500 mg/ml injection
The availability of this first WHO prequalified magnesium sulfate product marks an important milestone in the field of maternal health as this medicine is used to treat pre-eclampsia/eclampsia, the second most common cause of maternal deaths worldwide.
The prequalification process benefited from the technical assistance of Concept Foundation, and the support of the United Nations Commission on Life-Saving commodities for Women and Children (UNCoLSC), the Packard Foundation, as well as the USAID-Accelovate program.